Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

BMC Neuroscience 2012, 13:33 doi:10.1186/1471-2202-13-33

Kerry Hunter and Christian Holscher

OPEN ACCESS, FULL TEXT PDF

"Conclusions:
Our results suggest that these novel incretin analogues cross the BBB and show physiological activity and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases."